

Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Thursday 25 August 2016: 10.00 – 15.00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:	1. Prof. Gary McVeigh, Chair 2. Dr Lindsay Smith, Vice Chair 3. Dr Andrew Black 4. Prof. David Bowen 5. Dr Matthew Bradley 6. Dr Ian Campbell 7. Mrs Susan Dutton 8. Mrs Gillian Ells 9. Prof. Paula Ghaneh 10. Dr Susan Griffin 11. Prof. John Henderson 12. Dr David Meads 13. Mr Malcolm Oswald 14. Prof. Oluwafemi Oyebode 15. Dr Paula Parvulescu	Present for all notes Present for all notes
-----------------	--	---

In attendance:

Nigel Armstrong	ERG Representative, Kleijnen Systematic Reviews Ltd	Present for notes 1 to 13
Dr Tim Benepal	Clinical Expert, Consultant Medical Oncologist, nominated by the British Thoracic Oncology Group	Present for notes 17 to 25
Miriam Brazzelli	ERG Representative, Aberdeen HTA Group	Present for notes 17 to 25
Karen Clayton	Patient Expert, Macmillan Lung Cancer Nurse, nominated by the National Lung Cancer Forum for Nurses	Present for notes 17 to 25
Sophie Cooper	Technical Lead, National Institute for Health and Care Excellence	Present for notes 1 to 16

Joanne Ekeledo	Administrator, National Institute for Health and Care Excellence	Present for all notes
Charles Gore	Patient Expert, nominated by the Hepatitis C Trust	Present for notes 1 to 13
Dr Syed Hyder Hussaini	Clinical Expert, Consultant Hepatologist, nominated by the British Society of Gastroenterology	Present for notes 1 to 13
Manuela Joore	ERG Representative, Kleijnen Systematic Reviews Ltd	Present for notes 1 to 13
Helen Knight	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Professor Carole Longson	Centre Director, National Institute for Health and Care Excellence	Present for all notes
Kelvin Marshall	Patient Expert, nominated by Liver4Life	Present for notes 1 to 13
Fay McCracken	Technical Advisor, National Institute for Health and Care Excellence	Present for notes 17 to 29
Nicola McMeekin	ERG Representative, Aberdeen HTA Group	Present for notes 17 to 25
Kate Moore	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Xavier Pouwels	ERG Representative, Kleijnen Systematic Reviews Ltd	Present for notes 1 to 13
Malcolm Qualie	NHS Commissioning expert, nominated by NHS England	Present for notes 1 to 13 and 17 to 25
Dr Stephen Ryder	Clinical Expert, Consultant Hepatologist, Nottingham University Hospitals, nominated by Gilead	Present for notes 1 to 13
Amaka Umeweni	Technical Advisor, National Institute for Health and Care Excellence	Present for notes 1 to 16
Stuart Wood	Technical Lead, National Institute for Health and Care Excellence	Present for notes 17 to 29

Olivia Wu

ERG Representative,
Aberdeen HTA Group

Present for notes 17 to 25

Non-public observers:

Ann Greenwood	Senior Medical Editor, National Institute for Health and Care Excellence	Present for all notes
Caroline Hayto	CDF Administrator, National Institute for Health and Care Excellence	Present for all notes
Laura Norburn	Public involvement programme, National Institute for Health and Care Excellence	Present for all notes
Helen Powell	Technical Lead, National Institute for Health and Care Excellence	Present for all notes
Abi Senthinathan	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Maroulla Whiteley	Business Analyst - Resource Impact Assessment, National Institute for Health and Care Excellence	Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of sofosbuvir-velpatasvir for treating chronic hepatitis C and pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
2. The Chair informed the Committee of the non-public observers at this meeting: Ann Greenwood, Caroline Hayto, Laura Norburn, Helen Powell, Abi Senthinathan, and Marouella Whiteley,
3. Apologies were received from Dr Aomesh Bhatt, Ms Tracey Cole, Dr Ian Davidson, Professor Simon Dixon, Dr Alexander Dyker, Professor Carol Haigh, Dr Tim Kinnaird, Miss Sumithra Maheswaran and Dr Mohit Sharma.

Any other Business

4. None.

Part 1 – Open session

5. The Chair welcomed the invited experts: Nigel Armstrong, Charles Gore, Manuela Joore, Kelvin Marshall, Xavier Pouwels, Malcolm Qualie, Dr Syed Hyder Hussaini, and Dr Stephen Ryder to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Gilead to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Andrew Black, Professor David Bowen, Dr Matthew Bradley, Dr Ian Campbell, Mrs Susan Dutton, Mrs Gillian Ells, Professor Paula Ghaneh, Professor John Henderson, Dr David Meads, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, and Dr Paula Parvulescu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sofosbuvir-velpatasvir for treating chronic hepatitis C.
 - 7.2. Dr Susan Griffin declared a non-personal specific financial interest as she had previously been involved in a scoping project, commissioned through the Policy Research Programme, University of York, on behalf of NHS England, to look at treatment of hepatitis C in the UK. She was also a member of the Evidence Review Group for another hepatitis C appraisal.
 - 8.2.1 It was agreed that this declaration would not prevent Dr Susan Griffin from participating in this section of the meeting.
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sofosbuvir-velpatasvir for treating chronic hepatitis C.
9. The Chair asked all other invited guests to declare their relevant interests.
 - 9.1. Nigel Armstrong, Tim Benepal, Karen Clayton, Dr Syed Hyder Hussaini, Manuela Joore, Xavier Pouwels, and Malcolm Qualie declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sofosbuvir-velpatasvir for treating chronic hepatitis C.

- 9.2. Charles Gore declared a personal non-specific financial interest as the Hepatitis C Trust had received funding from Gilead and comparator companies involved in this appraisal.
 - 9.2.1. It was agreed that this declaration would not prevent Charles Gore from participating in this section of the meeting
- 9.3. Kelvin Marshall declared a personal non-specific financial interest Liver4Life had received educational grants from Gilead.
 - 9.3.1. It was agreed that this declaration would not prevent Kelvin Marshall from participating in this section of the meeting
- 9.4. Dr Stephen Ryder declared a personal non-specific financial interest as he is an Advisory Board for Gilead.
 - 9.4.1. It was agreed that this declaration would not prevent Dr Stephen Ryder from participating in this section of the meeting

10. The Chair introduced the lead team, Professor Carol Haigh, Professor John Henderson and Mr Malcolm Oswald, who gave presentations on the clinical effectiveness and cost effectiveness of sofosbuvir-velpatasvir for treating chronic hepatitis C.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of sofosbuvir-velpatasvir for treating chronic hepatitis C.
 - 15.1. The committee decision was based on consensus.
16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy [ID 840]

Part 1 – Open session

17. The Chair welcomed the invited experts: Dr Tim Benepal, Miriam Brazzelli, Karen Clayton, Nicola McMeekin, Malcolm Qualie and Olivia Wu to the meeting and they introduced themselves to the Committee.
18. The Chair welcomed company representatives from Merck Sharp & Dohme UK to the meeting.
19. The Chair asked all Committee members to declare any relevant interests
 - 19.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Andrew Black, Professor David Bowen, Dr Matthew Bradley, Dr Ian Campbell, Mrs Susan Dutton, Mrs Gillian Ells, Professor Paula Ghaneh, Dr David Meads, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, and Dr Paula Parvulescu declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
 - 19.2. Professor John Henderson declared a non-personal specific financial interest as his institution had received funding from Pfizer for unrelated research and a personal specific financial interest as he had received speaker fees from Novartis for an unrelated educational meeting.
 - 19.2.1 It was agreed that this declaration would not prevent Professor John Henderson from participating in this section of the meeting.
 - 19.3. Dr Susan Griffin declared a personal specific financial interest as she had taken part in an advisory board in November 2015 and was personally reimbursed by Novartis. The topic of the advisory board related to non-small cell lung cancer.
 - 19.3.1 It was agreed that this declaration would not prevent Dr Susan Griffin from participating in this section of the meeting.
20. The Chair asked all NICE Staff to declare any relevant interests.
 - 20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.

21. The Chair asked all other invited guests to declare their relevant interests.
 - 21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
22. The Chair introduced the key themes around the clinical effectiveness and cost effectiveness of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.
25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued. This information was supplied by the company.
27. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
 - 27.1. The committee decision was based on consensus.
28. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

29. Wednesday 28 September 2016, 10.00 – 17.00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.